Jump Financial LLC Decreases Stock Holdings in Amgen Inc. $AMGN

Key Points

• Jump Financial LLC reduced its shareholding in Amgen Inc. by 62.5% during the first quarter, resulting in ownership of 1,512 shares valued at approximately $471,000.
• Several large investors have made moves regarding Amgen's stock, with First Pacific Financial increasing their stake by 304.5% to own 89 shares valued at $28,000.
• Amgen declared a quarterly dividend of $2.38 per share, representing an annualized yield of 3.3%, with a dividend payout ratio of 77.84%.

Jump Financial LLC reduced its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 62.5% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,512 shares of the medical research company's stock after selling 2,522 shares during the quarter. Jump Financial LLC's holdings in Amgen were worth $471,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in AMGN. Pinney & Scofield Inc. purchased a new stake in shares of Amgen during the fourth quarter worth about $26,000. First Pacific Financial raised its position in Amgen by 304.5% during the 1st quarter. First Pacific Financial now owns 89 shares of the medical research company's stock valued at $28,000 after purchasing an additional 67 shares during the last quarter. Heck Capital Advisors LLC bought a new stake in shares of Amgen in the 4th quarter worth approximately $36,000. Global Wealth Strategies & Associates grew its position in shares of Amgen by 1,388.9% in the 1st quarter. Global Wealth Strategies & Associates now owns 134 shares of the medical research company's stock worth $42,000 after buying an additional 125 shares during the last quarter. Finally, Copia Wealth Management purchased a new position in shares of Amgen during the fourth quarter valued at approximately $45,000. Institutional investors own 76.50% of the company's stock.

Insider Activity

In related news, SVP Nancy A. Grygiel sold 1,267 shares of the company's stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total value of $376,286.33. Following the transaction, the senior vice president owned 7,209 shares in the company, valued at $2,141,000.91. The trade was a 14.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Rachna Khosla sold 1,500 shares of the stock in a transaction dated Thursday, June 5th. The shares were sold at an average price of $289.68, for a total transaction of $434,520.00. Following the sale, the senior vice president directly owned 8,162 shares in the company, valued at $2,364,368.16. This trade represents a 15.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.69% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of analysts recently commented on AMGN shares. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $305.00 price target on shares of Amgen in a research note on Tuesday, June 24th. Erste Group Bank lowered shares of Amgen from a "strong-buy" rating to a "hold" rating in a research note on Thursday, May 8th. Mizuho increased their price target on shares of Amgen from $235.00 to $280.00 and gave the stock a "neutral" rating in a research note on Wednesday, May 7th. Piper Sandler raised their price objective on shares of Amgen from $328.00 to $342.00 and gave the stock an "overweight" rating in a report on Monday, August 25th. Finally, Guggenheim assumed coverage on Amgen in a report on Tuesday, May 20th. They set a "neutral" rating and a $288.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Amgen has a consensus rating of "Hold" and an average target price of $304.43.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $287.71 on Tuesday. The company has a 50 day simple moving average of $293.44 and a two-hundred day simple moving average of $292.85. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $339.17. The company has a market capitalization of $154.89 billion, a price-to-earnings ratio of 23.52, a P/E/G ratio of 2.50 and a beta of 0.49. The company has a debt-to-equity ratio of 7.24, a quick ratio of 0.98 and a current ratio of 1.31.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The medical research company reported $6.02 earnings per share for the quarter, topping the consensus estimate of $5.28 by $0.74. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The company had revenue of $9.18 billion for the quarter, compared to the consensus estimate of $8.86 billion. During the same quarter in the prior year, the business posted $4.97 EPS. The firm's quarterly revenue was up 9.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. Analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, September 12th. Stockholders of record on Friday, August 22nd will be issued a dividend of $2.38 per share. The ex-dividend date is Friday, August 22nd. This represents a $9.52 annualized dividend and a dividend yield of 3.3%. Amgen's dividend payout ratio (DPR) is presently 77.84%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.